MDM2

MDM2 inhibitors disrupt the binding of mouse double minute 2 homolog (MDM2) to the tumor suppressor p53. In 1992 the MDM2 protein was shown to form a complex with p53 and inhibit p53-mediated transactivation. MDM2 is also an E3 ubiquitin ligase that promotes the rapid degradation of p53, as reported in 1997. Nutlins, reported in 2004, occupy the p53-binding pocket of MDM2 and activate the p53 pathway in cells and in vivo. Nutlin 3a is the active enantiomer of nutlin-3, and Nutlin 3b is a much weaker enantiomer used as a control. RG7112 and APG-115 are further MDM2 inhibitors, while MD-224 is a degrader that removes MDM2 protein. SJ 172550 targets the MDM2 relative MDM4 (also called MDMX).

Items 76-100 of 112

  • ISA 27
    Cat. No.
    A53841

    ISA 27

    ISA 27 is a small-molecule inhibitor of the MDM2-p53 protein-protein interaction. It effectively inhibits MDM2-mediated ubiquitination and degradation of p53, thereby stabilizing p53 levels. This compound is valuable for research on p53-mutant solid tumors, including thyroid and breast cancers, and offers a potential therapeutic strategy for targeting aberrant p53 signaling pathways.

    Out of stock

    All 3 sizes
  • MDM2-IN-21
    Cat. No.
    A53842

    MDM2-IN-21

    MDM2-IN-21 is a potent inhibitor of the MDM2 protein, which plays a critical role in the regulation of the p53 tumor suppressor pathway. By disrupting the MDM2-p53 interaction, MDM2-IN-21 activates p53-dependent signaling, leading to enhanced apoptosis and cell cycle arrest in cancer cells. This compound is widely utilized in cancer research to explore therapeutic strategies targeting MDM2 and to investigate its role in tumorigenesis and cellular responses to stress.

    5 mg
    $795.00
    All 1 sizes
  • RDR03871
    Cat. No.
    A53844

    RDR03871

    RDR03871 is a potent dual inhibitor of MDM2 and MDM4, demonstrating IC50 values of 35.4 nM and 10.4 nM for the MDM2-p53 and MDM4-p53 interactions, respectively. This compound plays a significant role in cancer research by modulating p53 pathways, thus offering a potential therapeutic avenue for tumors with dysregulated MDM2/MDM4 signaling. RDR03871 is suitable for studies focused on the restoration of p53 function in malignancies.

    1 mg
    $55.00
    5 mg
    $130.00
    All 6 sizes
  • MI-888 TFA
    Cat. No.
    A53845

    MI-888 TFA

    MI-888 TFA is a potent MDM2-p53 interaction inhibitor with a Ki of 0.44 nM, demonstrating notable efficacy in disrupting the MDM2-p53 complex. This compound exhibits rapid, complete, and sustained tumor regression in xenograft mouse models, making it a valuable tool in cancer research. MI-888 TFA is suitable for studies investigating the modulation of p53 pathways and its potential therapeutic applications in oncology.

    Out of stock

    All 3 sizes
  • BI-0282
    Cat. No.
    A53849

    BI-0282

    BI-0282 is a potent inhibitor of the MDM2-p53 interaction. This compound disrupts the negative regulation of the p53 tumor suppressor by MDM2, thereby enhancing p53-mediated transcriptional activity. BI-0282 is primarily used in research applications focused on cancer therapy, specifically in studies aimed at restoring p53 function in tumor cells. Its ability to stabilize p53 makes it a valuable tool for exploring therapeutic strategies targeting MDM2 in various malignancies.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • RO 2468
    Cat. No.
    A53854

    RO 2468

    RO 2468 is a potent and selective inhibitor of the p53-MDM2 interaction, designed for oral administration. This compound exhibits significant anti-proliferative activity, effectively reducing cell growth in SJSA1 osteosarcoma models while demonstrating minimal toxicity. RO 2468 is utilized in research focused on tumor suppression and the modulation of p53 signaling pathways.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • MI-888
    Cat. No.
    A53858

    MI-888

    MI-888 is a potent, orally active MDM2 inhibitor with a Ki of 0.44 nM, specifically designed to disrupt the MDM2-p53 interaction. This regulatory inhibition is critical for reactivating p53 signaling pathways, promoting apoptosis in cancer cells. With favorable pharmacokinetic properties, MI-888 demonstrates significant anti-tumor activity, making it a valuable tool for cancer research and therapeutic development.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • SP-141 hydrochloride
    Cat. No.
    A53860

    SP-141 hydrochloride

    SP-141 hydrochloride is a selective inhibitor of MDM2, a key negative regulator of the tumor suppressor p53. By promoting MDM2 auto-ubiquitination and subsequent degradation, SP-141 enhances p53 activity, which can induce apoptosis in cancer cells. This compound is primarily utilized in research focused on pancreatic and breast cancer, providing insights into MDM2-related pathways and potential therapeutic strategies.

    Out of stock

    All 3 sizes
  • YL93
    Cat. No.
    A53861

    YL93

    YL93 is a MDM2/4 dual inhibitor, exhibiting Ki values of 0.64 μM for MDM4 and 1.1 nM for MDM2. This compound effectively induces cell-cycle arrest and promotes apoptosis in p53-dependent contexts. YL93 is valuable for research applications focused on cancer biology and the modulation of p53 signaling pathways.

    Out of stock

    All 3 sizes
  • MDM2/4-p53-IN-1
    Cat. No.
    A53862

    MDM2/4-p53-IN-1

    MDM2/4-p53-IN-1 is an effective inhibitor of both MDM2-p53 and MDM4-p53 interactions, exhibiting IC50 values of 35.9 nM and 57.4 nM, respectively. This compound demonstrates significant antiproliferative activity, making it a valuable tool for cancer research and therapeutic studies targeting p53 pathways. Its ability to modulate p53 activity positions it as a promising candidate for investigations into tumorigenesis and potential cancer treatments.

    Out of stock

    All 3 sizes
  • MDM2/XIAP-IN-2
    Cat. No.
    A53864

    MDM2/XIAP-IN-2

    MDM2/XIAP-IN-2 is a dual inhibitor targeting murine double minute 2 (MDM2) and X-linked inhibitor of apoptosis protein (XIAP). This compound promotes the degradation of MDM2 and interferes with XIAP mRNA translation, effectively hindering the proliferation of cancer cells. Notably, MDM2/XIAP-IN-2 demonstrates potent activity against the acute lymphoblastic leukemia cell line EU-1, with an IC50 value of 0.3 μM, making it a valuable tool for cancer research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • RG7112D
    Cat. No.
    A53867

    RG7112D

    RG7112D is a potent MDM2 inhibitor that demonstrates IC50 values of 11 nM for MDM2-p53 and >10,000 nM for VHL-HIF1α, as assessed by HTRF assays. This compound is designed as a bi-functional molecule, YX-02-030, through an amide bond with VHL-Amine, enhancing its activity as a MDM2-PROTAC. RG7112D effectively stabilizes MDM2 protein and elevates p53 protein levels, making it a valuable tool for research in cancer biology and therapeutic applications targeting the p53 pathway.

    Out of stock

    All 3 sizes
  • Caylin-1
    Cat. No.
    A53872

    Caylin-1

    Caylin-1 is a potent inhibitor of MDM2, functioning through direct binding to the protein to disrupt its interaction with p53. This compound is an analog of Nutlin-3 and exhibits additional binding affinity to Bcl-XL, making it a valuable tool in multi-target anticancer research. Caylin-1's unique properties facilitate investigations into oncogenic pathways and the therapeutic potential of cancer treatments targeting both MDM2 and Bcl-XL.

    1 mg
    $140.00
    5 mg
    $550.00
    All 3 sizes
  • MD-265
    Cat. No.
    A53880

    MD-265

    MD-265 is a potent MDM2 degrader utilizing the PROTAC (PROteolysis TArgeting Chimeras) technology. It effectively promotes the degradation of MDM2, resulting in the reactivation of the p53 tumor suppressor pathway in cancer cells with wild-type p53. Preclinical studies demonstrate that MD-265 induces complete tumor regression and enhances long-term survival in leukemia models, making it a valuable tool for cancer research and therapeutic development.

    1 mg
    $575.00
    5 mg
    $1,475.00
    All 2 sizes
  • WB156
    Cat. No.
    A53881

    WB156

    WB156 is a dual degrader targeting MDM2 and GSPT1, facilitating their degradation through the recruitment of Cereblon (CRBN) to the ubiquitin-proteasome pathway. This compound effectively induces ubiquitination, leading to a reduction in MDM2 and GSPT1 levels, which is valuable for investigating the role of these proteins in cancer biology. WB156 holds potential for research applications in various cancer types, including leukemia.

    Out of stock

    All 3 sizes
  • TB114
    Cat. No.
    A53885

    TB114

    TB114 is a selective inhibitor of the MDM2 protein, demonstrating a Ki value of 0.4 nM. By inhibiting MDM2, TB114 enhances the tumor-suppressive functions of p53, leading to increased apoptosis in cancer cells. This compound holds significant promise for research applications focused on cancer therapies that target the MDM2-p53 interaction.

    Out of stock

    All 3 sizes
  • Siremadlin succinate
    Cat. No.
    A53886

    Siremadlin succinate

    Synonyms: NVP-HDM201 succinate; HDM201 succinate

    Siremadlin succinate is a potent MDM2 inhibitor that selectively targets the p53-binding pocket of MDM2, disrupting its ability to mediate the ubiquitination and degradation of the p53 tumor suppressor. By activating the p53 pathway, Siremadlin succinate promotes p53-dependent cell cycle arrest and apoptosis in p53 wild-type cells. This compound is valuable for research applications focused on cutaneous melanoma and other cancers with dysregulated p53 signaling.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • NVP-CFC218
    Cat. No.
    A53891

    NVP-CFC218

    NVP-CFC218 is a selective inhibitor targeting the TP53-MDM2 interaction, effectively displacing the p53 peptide from HDM2 with an IC50 value of 1.6 nM. This compound is instrumental in assessing pharmacological sensitivity in various cell line models and is widely utilized in cancer research to study tumor suppressor pathways and MDM2-mediated p53 regulation.

    25 mg
    $1,905.00
    50 mg
    $2,445.00
    All 3 sizes
  • Phage-derived 12/1 peptide
    Cat. No.
    A53894

    Phage-derived 12/1 peptide

    Phage-derived 12/1 peptide is a potent inhibitor of the MDM2/p53 interaction, effectively disrupting the binding between MDM2 and p53, as well as MDMX and p53. This peptide demonstrates significant antitumor activity, exhibiting IC50 values of 0.15 μM for MDM2 and 1.25 μM for MDMX. It serves as a valuable tool for research investigating the modulation of p53 activity and the therapeutic potential in targeting MDM2/MDMX pathways in cancer.

    Out of stock

    All 3 sizes
  • pDI
    Cat. No.
    A53896

    pDI

    pDI is a synthetic peptide that functions as an inhibitor of the MDM2 and MDMX-p53 interactions, exhibiting half-maximal inhibitory concentrations (IC50) of 10 nM and 100 nM, respectively. This compound is essential for research focused on colorectal cancer, providing insights into tumor suppression mechanisms and the modulation of p53 activity. Its ability to disrupt these critical protein-protein interactions makes pDI a valuable tool in cancer therapeutic studies.

    Out of stock

    All 3 sizes
  • MI-219
    Cat. No.
    A53898

    MI-219

    MI-219 is an MDM2 antagonist with a Ki of 13.3 μM, specifically designed to disrupt the interaction between MDM2 and p53. This compound effectively inhibits the proliferation of FSCCL cells, demonstrated by an IC50 of 2.5 μM. MI-219 is suitable for research applications focused on cancer biology, particularly in studies exploring pathways related to tumor suppression and the p53 signaling axis.

    25 mg
    $2,645.00
    50 mg
    $4,100.00
    All 3 sizes
  • p53-MDM2-IN-2
    Cat. No.
    A53901

    p53-MDM2-IN-2

    p53-MDM2-IN-2 is an orally active inhibitor targeting the p53-MDM2 interaction, exhibiting a Ki value of 0.25 μM. This compound demonstrates antitumor activity through the inhibition of the NF-κB signaling pathway. It is valuable in research studies focusing on cancer therapy and elucidating the molecular mechanisms of tumor suppression.

    1 mg
    $130.00
    5 mg
    $570.00
    All 4 sizes
  • MI-1063
    Cat. No.
    A53902

    MI-1063

    MI-1063 is a selective inhibitor of MDM2 that disrupts the MDM2-p53 interaction, thereby activating the tumor suppressor activity of p53. This compound effectively inhibits the proliferation of cancer cell lines RS4-11 and MV4-11, demonstrating IC50 values of 179 nM and 93 nM, respectively. Additionally, MI-1063 serves as a valuable target protein ligand in the synthesis of the PROTAC degrader MD-265, facilitating advancements in targeted protein degradation research.

    Out of stock

    All 3 sizes
  • MDM2-IN-26
    Cat. No.
    A53903

    MDM2-IN-26

    MDM2-IN-26 is an inhibitor targeting MDM2, a critical negative regulator of the tumor suppressor p53. By disrupting the MDM2-p53 interaction, this compound effectively activates p53's tumor suppressor functions, providing a promising approach for cancer research. MDM2-IN-26 can be utilized to study the modulation of p53 activity in various cancer models and therapeutic applications.

    Out of stock

    All 3 sizes
  • Nutlin 1
    Cat. No.
    A53904

    Nutlin 1

    Nutlin 1 is a potent MDM2 antagonist that reactivates the p53 pathway, playing a critical role in cell cycle regulation and apoptosis. With an IC50 of 0.26 μM, it effectively disrupts the MDM2-p53 interaction, promoting p53-mediated transcriptional activity. This compound is widely used in cancer research to explore the therapeutic potential of p53 reactivation in tumor cells.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

Items 76-100 of 112

Added to your cart

View Cart Checkout

    Loading...